SCCmec Type IV, PVL-Negative, Methicillin-Resistant Staphylococcus aureus in Cystic Fibrosis Patients from Brazil.

Current Microbiology
Marcelo Jenne MimicaRozane Bigelli Carvalho

Abstract

Twenty seven S. aureus isolates were obtained from cystic fibrosis (CF) patients at a tertiary care hospital in Brazil. Nineteen (70.4%) were methicillin-susceptible S. aureus (MSSA) and eight (29.6%) methicillin-resistant S. aureus (MRSA). Of the MRSA isolates, four had SCCmec type III and four had SCCmec type IV. PVL genes were not detected in any of the MSSA or MRSA isolates. New studies are necessary to evaluate the exact impact of these different MRSA clones in CF patients.

References

Feb 13, 2001·Archives of Disease in Childhood·L S MiallS P Conway
Mar 8, 2005·The Pediatric Infectious Disease Journal·Ana M Avalos MishaanKristina Hulten
Mar 29, 2006·The Pediatric Infectious Disease Journal·Kristina G HulténEdward O Mason
Jan 20, 2007·Science·Maria Labandeira-ReyM Gabriela Bowden

❮ Previous
Next ❯

Citations

Dec 14, 2011·The Journal of Infection·Maria Fernanda Bádue PereiraEitan Naaman Berezin
Mar 14, 2014·Journal of Chemotherapy·Maria Fernanda B PereiraMarcelo J Mimica
Aug 26, 2011·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Marcelo J Mimica
May 11, 2016·Revista Da Sociedade Brasileira De Medicina Tropical·Jessica Baleiro OkadoIlana Lopes Baratella da Cunha Camargo
Oct 22, 2020·The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Médicale·Mariana Moreira AndradeJaime Henrique Amorim

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

© 2021 Meta ULC. All rights reserved